ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1733

Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease

Nozima Aripova1, Michael Duryee1, Amy Nelson1, Carlos Hunter1, Breanna Butler1, Bryant England1, Jill Poole1, Geoffrey Thiele1 and Ted R Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Growth Factor, interstitial lung disease, pulmonary, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1713–1733) RA – Animal Models Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a leading cause of mortality in RA with limited treatment options as well as lack of available animal modeling systems for preclinical investigations. We previously demonstrated that co-exposure of the collagen induced arthritis (CIA) with repetitive airborne lipopolysaccharide (LPS) exposure leads to increased autoimmunity, arthritis, and pro-fibrotic/pro-inflammatory lung disease. In addition to recapitulating important histopathologic features of RA-ILD, this model demonstrates more severe arthritis and lung manifestations in male mice. Platelet-derived growth factor (PDGF)-BB and its receptor (PDGFR) are important cellular proliferation and growth with dysregulation associated with cancers and tissue fibrosis, with limited and conflicting studies in RA. In the present study, we leveraged our novel mouse preclinical animal modeling system to investigate the potential role of PDGF-BB/PDGFR, in RA-associated lung disease.

Methods: Arthritis-prone male (DBA/1J) mice (n=5/group) received either: Sham (saline injection/inhalation), CIA (CIA on day 1 and 21/saline inhalation), LPS (saline injection/ LPS 100ng inhalation), or CIA+LPS (CIA injection/LPS inhalation) for 5 weeks. At week 5, serum was collected for quantification of PDGF-BB using ELISA in all 4 groups. Based on marked serum differences observed between CIA+LPS and Sham, lung tissues were isolated for quantification of PDGF-BB and PDGF-receptor expression using fluorescent immunohistochemistry (IHC) in these two treatment groups. Serum PDGF-BB levels were compared using one-way ANOVA and Bonferroni multiple comparison tests across the 4 treatment groups. Fluorescent IHC, expressed in mean pixel density, was quantified and compared in CIA+LPS vs. Sham-treated mice using a t-test.

Results: Serum PDGF-BB concentrations (pg/ml mean ± SEM) were the highest in the CIA+LPS group (1.6×104 ± 1.2×103; p< 0.05 vs. all others) (Figure 1). Also, serum PDGF-BB levels were significantly increased in CIA group (1.1×104 ± 5.5×102) compared to Sham (4.7×103 ± 1.1×102; p< 0.05) and LPS (6.9×103 ± 8.8×102; p< 0.05) groups. Staining of lung tissues demonstrated that PDGF-BB expression was decreased significantly in CIA+LPS compared to Sham (p< 0.01) (Figure 2). In contrast, PDGF-receptor expression was increased significantly in CIA+LPS (p< 0.0001) compared to Sham.

Conclusion: Co-exposure of mice to CIA+LPS profoundly increased circulating PDGF-BB concentrations. In the corresponding lung tissues of CIA+LPS mice, PDGF-BB expression was strikingly reduced while PDGF-receptor expression was increased. These findings imply that dual exposure modulate the PDGF-BB/PDGFR pathway that release and/or production of PDGF is altered. Moreover, these observations suggest that PDGF-BB may serve as an important mediator of the inflammatory and fibrotic processes underlying RA-ILD pathogenesis and could represent a potential novel target for treatment.

Supporting image 1

Figure 1. PDGF-BB levels in the serum of DBA mice. Mice were treated with/without CIA and with/without LPS inhalation. Scatter dot plots represent mean±SEM of platelet-derived growth factor (PDGF) levels (pg/mL). Comparisons made to Sham are illustrated above each bar: ***p<0.001, *p<0.05, n=4. Tukey’s post-hoc test comparisons are illustrated between treatment groups, and only significant differences are illustrated: ***p<0.001, *p<0.05. Abbreviations: CIA, collagen-induced arthritis; LPS, lipopolysaccharide.

Supporting image 2

Figure 2. IHC Staining of Lung Tissue from DBA mice. Mice were treated with CIA+LPS or Sham-Saline. Lung tissues were stained for: (A) PDGF; and (B) PDGF-receptor. The data is represented as a mean of integrated density with SEM. Comparisons between the two groups were made using t-test: **p<0.01. Abbreviations: CIA, collagen-induced arthritis; LPS, lipopolysaccharide; PDGF, platelet-derived growth factor.


Disclosures: N. Aripova: None; M. Duryee: None; A. Nelson: None; C. Hunter: None; B. Butler: None; B. England: Boehringer-Ingelheim, 2, 5; J. Poole: AstraZeneca, 12, I have received no monies. I received anti-IL-33 monoclonal antibody from AstraZeneca for animal research sutdies.; G. Thiele: None; T. Mikuls: Elsevier, 9, Horizon Therapeutics, 2, 5, Pfizer, 2, Sanofi, 2, UCB Pharma, 2, Wolters Kluwer Health (UpToDate), 9.

To cite this abstract in AMA style:

Aripova N, Duryee M, Nelson A, Hunter C, Butler B, England B, Poole J, Thiele G, Mikuls T. Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/platelet-derived-growth-factor-is-a-mediator-of-disease-in-an-animal-model-of-rheumatoid-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/platelet-derived-growth-factor-is-a-mediator-of-disease-in-an-animal-model-of-rheumatoid-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology